Several years ago, a little-known drug named Ozempic – previously used only to treat diabetes – emerged as a promising new drug for weight management. The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class of drugs called glucagon-like peptide-1 agonists,

The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an assessment of how the drugs affect 175 conditions

Debate over the risks and benefits of the population weight loss drugs like Ozempic, Wegovy, and Zepbound finally came to an end after a new landmark study.According to Global News, a new observational study published in the journal

A study by the Department of Veterans Affairs says that drugs like Ozempic can do plenty more than just help with weight loss.

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 receptor agonists.

Weight-loss medicines such as Ozempic might raise a person’s likelihood of developing conditions including arthritis.

Researchers took drugs currently used to treat type 2 diabetes and obesity and looked into how they affect 175 conditions. They found people taking the jabs were less likely to develop health problems like psychotic disorders, heart disease and dementia.

The newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ways they affect the body—both helpful and harmful—beyond reducing weight. In report published in Nature Medicine,

Weight-loss drugs like Ozempic may decrease your risk of developing 42 health conditions, but increase your chance of experiencing 19 others, according to one of the most comprehensive studies-of-its-kind to date.